Abstract
The first draft diploid genome assembly (HuRef) of an individual released in 2007 was a milestone in genomics. Here, we report HuRef2.0, a revision of HuRef assembled using a scalable two-step workflow employing only Oxford Nanopore Technologies (ONT) Simplex reads and the hifiasm assembler. Results are close in continuity to the recent telomere-to-telomere (T2T) assemblies, but were assembled from standard DNA samples without using multiple sequencing and mapping technologies, including ultra-long-reads and/or proximity-ligation. Three ONT flowcells (∼103x coverage) from fresh blood DNA produced an assembly comprising 26 contigs, with gapless assembly of 23 chromosomes. Two gaps on chromosome (Chr)Y were locally assembled to yield the final T2T-assembly, HuRef2.0, with base accuracy >Q60 and 2,393 phase blocks with an NG50 value of 2.36 Mb. Assembly from a single ONT flowcell (∼35x coverage) consistently produced an assembly more contiguous than GRCh38.p14, providing a foundation for further optimization and scaling. Assembly quality was assessed by direct chromosome-level alignments to reference genome, variant calling, and the annotation of gene-rich regions at Chr22q11, the extended MHC locus on Chr6, and several difficult to assemble regions of the genome, including the ribosomal RNA gene clusters, the sub-telomeric region on Chr4q35, and ChrY. More accurate but shorter Pacific Biosciences (PacBio) HiFi-reads produced less contiguous assemblies than from equivalent coverage of error-corrected ONT reads, indicating the importance of read-length. Finally, we compared HuRef2.0 to an assembly of an EBV-transformed lymphoblastoid cell line derived from the same donor. We observed no notable structural differences, indicating that low-passage archival transformed cells are reliable sources for genomic analysis.
Competing Interest Statement
SWS sits in advisory capacity for Diploid Genomics, Deep Genomics, and Population Genomics. Intellectual property from his laboratory held in his name at the Hospital for Sick Children has been licensed by Athena Diagnostics.
Funding Statement
Funding support is from the Canada Foundation for Innovation to the CGEn National Genome Sequencing and Informatics Centre, the Lau Family Endowment in Genome Sciences, the University of Toronto McLaughlin Centre, and Genome Canada. SWS holds the Northbridge Chair in Paediatic Research at the Hospital for Sick Children and the University of Toronto
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for research completed in this publication was obtained from the Hospital for Sick Children Ethics Board (Approval No:1000053640). All procedures involving human participants were conducted in accordance with institutional guidelines. Written informed consent was obtained from the participant prior to their inclusion in the study. Also as described in the original paper describing the initial and ongoing project (Levy et al., PloS Biology, 2007; PMID: 17803354) the donor gave full consent to provide his DNA for study via sequencing methods and to disclose publicly his genomic data in totality. Moreover, also covered in this paper, the collection of DNA from blood with intended personal, medical, and phenotypic data was performed since that time on a regular basis. Ethical review of the study was performed annually. We acknowledge the statement on MedRxiv submission site that references that information cannot be included to be used to identify individuals. This study and the consent was designed specifically to deal with this upfront in the consent and the samples and sequences submitted have been used for reference in medical genomics studies accordingly.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All sequencing data used in the present study are deposited under BioProjects: PRJNA1266749, PRJNA12266743, and PRJNA1268575. Assemblies HuRef2.0, JCVblood-PB, JCVcellLine-PB are deposited at NCBI Genbank under the accession JBPPLP01, JBTWEK01, and JBPQOS01, respectively. Phased heterozygous sites and associated phase blocks of HuRef2.0 (with HuRef2.0 coordinates) can be downloaded from https://doi.org/10.5281/zenodo.19861724, together with the haplotype constructions of the extended MHC region, 22q11.2, 5S rDNA cluster, COL4A4 and RAD51C.





